Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX versus XELOX adjuvant chemotherapy for stage III colorectal cancer
ChiCTR1800020419Phase 4Not yet recruiting
- Sponsor
- Yixing People's Hospital
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegafur, capecitabine and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Yixing People's Hospital. Primary endpoint: 3-year disease-free survival rate. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
tegafurcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800020419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020419.